Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer: A Brief Report

Shiao, Tsu‐Hui; Chang, Yih‐Leong; Yu, Chong‐Jen; Chang, Yu‐Cheng; Hsu, Ya‐Chieh; Chang, Shih-Han; Shih, Jin‐Yuan; Yang, Pan‐Chyr

doi:10.1097/jto.0b013e3181f94abb

Cited by 86 publications

(75 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the study by Tatematsu et al, most of the specimens were obtained from biopsy (15). The specimens reported by Shiao et al include 10 computed tomography-guided biopsy specimens, 17 echo-guided aspiration specimens, 37 echo-guided biopsy specimens, one surgical lobectomy specimen and 11 malignant pleural effusion specimens (16), whereas, in the present study, all the specimens were obtained during surgery.…”

Section: Discussionmentioning

confidence: 59%

Mutation status of epidermal growth factor receptor and clinical features of patients with combined small cell lung cancer who received surgical treatment

Mao

Cheng

et al. 2012

Oncology Letters

View full text Add to dashboard Cite

Abstract. The mutation status of epidermal growth factor receptor (EGFR) is correlated with the response of tumors to EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC), suggesting its usefulness as a biomarker in NSCLC. The incidence of EGFR mutation in NSCLC is higher in China than in the United States and European countries. There have been some case reports concerning cases of gefitinib-responsive small cell lung cancer (SCLC) with EGFR mutations. However, few large studies concerning the mutation status of SCLC patients have been performed. We detected EGFR mutations in exons 19 and 21 of 40 SCLC patients, three of whom had combined SCLC, from the Zhejiang Cancer Hospital using xTAG technology. Only two patients with combined SCLC had an EGFR mutation in exon 19. To determine the EGFR mutation status and clinical features of combined SCLC, we retrospectively analyzed the clinical features of seven patients with combined SCLC who had undergone surgical treatment in Zhejiang Cancer Hospital between 2007 and 2010. EGFR mutations in exons 19 and 21 were detected using the pyrosequencing assay. Of the seven patients with combined SCLCs, 71.4% were male, 71.4% were heavy smokers, most were over 60 years old and 71.4% of the cases were combined adenocarcinoma. Chemotherapy treatment and tumor stage were correlated with survival time. Of the seven cases, one had a mutation in exon 19 of EGFR in both the conventional SCLC and SCLC combined adenocarcinoma components. Combined SCLC commonly occurs in patients who are heavy smokers, male and over 60 years old, and most of the combined type cases are adenocarcinoma. The treatment of combined SCLC may be applied to cases of conventional SCLC. EGFR mutations may therefore occur in combined SCLCs, especially in SCLC combined adenocarcinoma in China. IntroductionAn epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) may be used as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (1-5). The results of the INTEREST trial (6) suggest that gefitinib is able to provide similar overall survival to docetaxel in patients across a broad range of clinical subgroups and that EGFR biomarkers, including mutation status, may additionally identify which patients are likely to gain greatest progression-free survival (PFS) and overall response rate (ORR) benefit from treatment with gefitinib. Two hot spots of EGFR mutations are in-frame deletion at codons 747-749 (DEL) in exon 19 and a missense mutation at codon 858 (L858R) in exon 21. A case study concerning a Japanese patient with gefitinib-responsive small cell lung cancer (SCLC) reported that the patient had a deletion in exon 19 of EGFR (7). Another case study has reported that an American SCLC patient who had never smoked and who had an EGFR mutation responded to gefitinib (8). In China, there has also been a case report of a patient with SCLC who responded to gefitinib, but the status of the mutation is unknown (9). Therefore, the EGFR mutation ...

show abstract

Section: Discussionmentioning

confidence: 59%

Mutation status of epidermal growth factor receptor and clinical features of patients with combined small cell lung cancer who received surgical treatment

Mao

Cheng

et al. 2012

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…A growing number of case reports have documented EGFR mutations in these cases raising the possibility of treatment with a tyrosine kinase inhibitor. 44 Other neuroendocrine tumors of the lung SCLC fits into the spectrum of neurocrine tumors of the lung as a high-grade tumor along with LCNEC and as a low-grade TC and intermediate-grade AC.…”

Section: Differential Diagnosismentioning

confidence: 99%

Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas

2012

View full text Add to dashboard Cite

Small cell lung cancer (SCLC) comprises 14% of all lung cancers, and 430 000 new cases are diagnosed per year in the United States. SCLC is one of the most distinctive malignancies in the entire field of oncology with characteristic clinical properties, responsiveness to specific chemotherapy, genetic features and a highly reliable pathological diagnosis. SCLC is defined by light microscopy, and the most important stain is a goodquality hematoxylin and eosin (H&E)-stained section. The vast majority of cases can be diagnosed on H&E alone; however, in problem cases, immunohistochemistry can be very helpful in making the distinction from other tumors. Cytology is also a powerful tool, often being more definitive than small biopsies with scant tumor cells, crush artifact and/or necrosis. As virtually all SCLCs present in advanced stages, most patients are diagnosed based on small biopsy and cytology specimens. Historically, there has been significant evolution in the histological subclassification of SCLC dating from 1962 when Kreyberg proposed the oat cell and polygonal cell types. The current subclassification recognizes only two subtypes: pure SCLC and combined SCLC. Pathologists need to do their best to make a diagnosis of SCLC or other histological types of lung cancer and this can be achieved in most cases. This review will address some of the diagnostic problems that occur in the minority of cases and outline practical ways to address them. Brief reference will be made to other neuroendocrine lung tumors with an overview of the molecular pathogenesis of this spectrum of tumors.

show abstract

“…The mutational analysis of EGFR genes was as previously reported (6,23,27). In summary, DNA was derived from tumors embedded in paraffin blocks by using a QIAmp DNA Mini Kit (Qiagen).…”

Section: Mutational Analysis Of Egfrmentioning

confidence: 99%

Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer

Yu²,

Chang³

et al. 2011

Clinical Cancer Research

Self Cite

413

341

View full text Add to dashboard Cite

Purpose: Clinical features of epidermal growth factor receptor (EGFR) mutations, L858R, deletions in exon 19, T790M, and insertions in exon 20, in non-small cell lung cancer (NSCLC) are well known. The clinical significance of other uncommon EGFR mutations, such as their association with the effectiveness of EGFR tyrosine kinase inhibitors (TKI), is not well understood. This study aimed to improve the understanding of these uncommon EGFR mutations of unknown clinical significance.Patients and Methods: Specimens from 1,261 patients were tested for EGFR mutations. We surveyed the clinical data and the effectiveness of gefitinib and erlotinib in NSCLC patients with uncommon EGFR mutations.Results: Of the 1,261 patients, 627 (49.8%) had EGFR mutations. This included 258 patients with deletions in exon 19, 260 patients with L858R, 25 patients with insertions or duplications in exon 20, 6 patients with de novo T790M, and 78 (12.4%) patients with uncommon mutations. Of the 78 patients, 62 received either gefitinib or erlotinib treatment. The response rate of TKIs treatment was 48.4%, and the median progression-free survival (PFS) was 5.0 months. Mutations on G719 and L861 composed a major part (28 of 62) of uncommon mutations, and were associated with a favorable effectiveness of EGFR TKIs (response rate, 57.1%; median PFS, 6.0 months). Mutations other than G719 and L861 led to a worse response to EGFR TKIs (response rate, 20.0%; median PFS, 1.6 months).Conclusions: Uncommon EGFR mutations constituted a distinct part of the whole group of EGFR mutations. Their composition was heterogeneous, and their associations with EGFR TKIs differed. Clin Cancer Res; 17(11); 3812-21. Ó2011 AACR.

show abstract

Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer: A Brief Report

Abstract: The EGFR mutation is rare in SCLC patients. Despite the presence of the EGFR mutation, gefitinib may not be effective in treating SCLC patients.

Cited by 86 publications

References 13 publications

Mutation status of epidermal growth factor receptor and clinical features of patients with combined small cell lung cancer who received surgical treatment

Mutation status of epidermal growth factor receptor and clinical features of patients with combined small cell lung cancer who received surgical treatment

Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas

Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer

Contact Info

Product

Resources

About